# A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

> **NCT02336048** · PHASE1 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 38 (actual)

## Conditions studied

- B-Cell Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Chlorambucil
- **DRUG:** Obinutuzumab
- **DRUG:** Placebo
- **OTHER:** Standard Premedication
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT02336048
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-26
- **Primary completion:** 2018-09-21
- **Final completion:** 2018-09-21
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** This study was terminated early because premedication with tocilizumab was unlikely to reduce the risk of IRR.
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02336048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02336048, "A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02336048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*